1
|
Weiss GR, Mita A, Garrison M, Chu SCQ, Syed S, Haider O, Bonate P, Hammond LA, Rowinsky EK. Phase I, pharmacokinetic (PK) study of synthadotin (SYN-D; ILX651), a next generation antitubulin, administered iv weekly x 3 weeks every 4 weeks (wx3q4w). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3073] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- G. R. Weiss
- University of TX Health Science Ctr at San Antonio, San Antonio, TX; Institute for Drug Development, CTRC, San Antonio, TX; Brooke Army Medical Center, San Antonio, TX; ILEX Products, Inc., San Antonio, TX
| | - A. Mita
- University of TX Health Science Ctr at San Antonio, San Antonio, TX; Institute for Drug Development, CTRC, San Antonio, TX; Brooke Army Medical Center, San Antonio, TX; ILEX Products, Inc., San Antonio, TX
| | - M. Garrison
- University of TX Health Science Ctr at San Antonio, San Antonio, TX; Institute for Drug Development, CTRC, San Antonio, TX; Brooke Army Medical Center, San Antonio, TX; ILEX Products, Inc., San Antonio, TX
| | - S.-C. Q. Chu
- University of TX Health Science Ctr at San Antonio, San Antonio, TX; Institute for Drug Development, CTRC, San Antonio, TX; Brooke Army Medical Center, San Antonio, TX; ILEX Products, Inc., San Antonio, TX
| | - S. Syed
- University of TX Health Science Ctr at San Antonio, San Antonio, TX; Institute for Drug Development, CTRC, San Antonio, TX; Brooke Army Medical Center, San Antonio, TX; ILEX Products, Inc., San Antonio, TX
| | - O. Haider
- University of TX Health Science Ctr at San Antonio, San Antonio, TX; Institute for Drug Development, CTRC, San Antonio, TX; Brooke Army Medical Center, San Antonio, TX; ILEX Products, Inc., San Antonio, TX
| | - P. Bonate
- University of TX Health Science Ctr at San Antonio, San Antonio, TX; Institute for Drug Development, CTRC, San Antonio, TX; Brooke Army Medical Center, San Antonio, TX; ILEX Products, Inc., San Antonio, TX
| | - L. A. Hammond
- University of TX Health Science Ctr at San Antonio, San Antonio, TX; Institute for Drug Development, CTRC, San Antonio, TX; Brooke Army Medical Center, San Antonio, TX; ILEX Products, Inc., San Antonio, TX
| | - E. K. Rowinsky
- University of TX Health Science Ctr at San Antonio, San Antonio, TX; Institute for Drug Development, CTRC, San Antonio, TX; Brooke Army Medical Center, San Antonio, TX; ILEX Products, Inc., San Antonio, TX
| |
Collapse
|
2
|
Bonate P, Ebbinghaus S, Eder JP, Mita A, Rubin E, Cunningham CC, Rowinsky EK, Hersh E, Craig AR, Hammond LA. Pharmacokinetics of synthadotin (ILX651), a novel tubulin polymerization inhibitor, in patients with solid tumors. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.2082] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- P. Bonate
- ILEX Products, Inc, San Antonio, TX; Arizona Cancer Center, Tucson, AZ; Dana Farber Cancer Institute, Boston, MA; Institute for Drug Development, CTRC, San Antonio, TX; Cancer Institute of New Jersey, New Brunswick, NJ; US Oncology, Mary Crowley Research Center, Dallas, TX
| | - S. Ebbinghaus
- ILEX Products, Inc, San Antonio, TX; Arizona Cancer Center, Tucson, AZ; Dana Farber Cancer Institute, Boston, MA; Institute for Drug Development, CTRC, San Antonio, TX; Cancer Institute of New Jersey, New Brunswick, NJ; US Oncology, Mary Crowley Research Center, Dallas, TX
| | - J. P. Eder
- ILEX Products, Inc, San Antonio, TX; Arizona Cancer Center, Tucson, AZ; Dana Farber Cancer Institute, Boston, MA; Institute for Drug Development, CTRC, San Antonio, TX; Cancer Institute of New Jersey, New Brunswick, NJ; US Oncology, Mary Crowley Research Center, Dallas, TX
| | - A. Mita
- ILEX Products, Inc, San Antonio, TX; Arizona Cancer Center, Tucson, AZ; Dana Farber Cancer Institute, Boston, MA; Institute for Drug Development, CTRC, San Antonio, TX; Cancer Institute of New Jersey, New Brunswick, NJ; US Oncology, Mary Crowley Research Center, Dallas, TX
| | - E. Rubin
- ILEX Products, Inc, San Antonio, TX; Arizona Cancer Center, Tucson, AZ; Dana Farber Cancer Institute, Boston, MA; Institute for Drug Development, CTRC, San Antonio, TX; Cancer Institute of New Jersey, New Brunswick, NJ; US Oncology, Mary Crowley Research Center, Dallas, TX
| | - C. C. Cunningham
- ILEX Products, Inc, San Antonio, TX; Arizona Cancer Center, Tucson, AZ; Dana Farber Cancer Institute, Boston, MA; Institute for Drug Development, CTRC, San Antonio, TX; Cancer Institute of New Jersey, New Brunswick, NJ; US Oncology, Mary Crowley Research Center, Dallas, TX
| | - E. K. Rowinsky
- ILEX Products, Inc, San Antonio, TX; Arizona Cancer Center, Tucson, AZ; Dana Farber Cancer Institute, Boston, MA; Institute for Drug Development, CTRC, San Antonio, TX; Cancer Institute of New Jersey, New Brunswick, NJ; US Oncology, Mary Crowley Research Center, Dallas, TX
| | - E. Hersh
- ILEX Products, Inc, San Antonio, TX; Arizona Cancer Center, Tucson, AZ; Dana Farber Cancer Institute, Boston, MA; Institute for Drug Development, CTRC, San Antonio, TX; Cancer Institute of New Jersey, New Brunswick, NJ; US Oncology, Mary Crowley Research Center, Dallas, TX
| | - A. R. Craig
- ILEX Products, Inc, San Antonio, TX; Arizona Cancer Center, Tucson, AZ; Dana Farber Cancer Institute, Boston, MA; Institute for Drug Development, CTRC, San Antonio, TX; Cancer Institute of New Jersey, New Brunswick, NJ; US Oncology, Mary Crowley Research Center, Dallas, TX
| | - L. A. Hammond
- ILEX Products, Inc, San Antonio, TX; Arizona Cancer Center, Tucson, AZ; Dana Farber Cancer Institute, Boston, MA; Institute for Drug Development, CTRC, San Antonio, TX; Cancer Institute of New Jersey, New Brunswick, NJ; US Oncology, Mary Crowley Research Center, Dallas, TX
| |
Collapse
|